The future of addiction therapy could soon look a lot like treatment for diabetes.

A California-based addiction treatment company hopes to change the way patients struggling with substance abuse disorder receive a popular form of medication-assisted treatment. If approved, patients could self-administer naltrexone, an opioid antagonist, in the comfort of their own homes — like insulin, but for recovering addicts.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Why is the Globe featuring articles on its paid homepage that require an additional paid subscription? Insultingly greedy move. Whoever decided that this was a good idea, is clueless.

  • Because off danger of precipitating an acute withdrawal reaction giving naltrexone to an active opiate user this should only be done in a medical setting. But hey, california dope fiends get “kicks” from your grand mal seizure if you want.

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy